PPD's Acurian subsidiary has expanded its relationship with the Society for Clinical Research Sites, a group representing thousands of trial outposts around the globe, focusing on improving patient recruitment.
Chemistry and biology are joining hands in China in ways that will have a profound impact on biotechnology startups and more established companies, but it is still early days for many companies and more money from venture capitalists or other funding sources is welcome.
PPD has amped up the biologics capabilities at its Irish manufacturing operation, opening a new lab devoted to the development of large-molecule treatments.
X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.
PPD has signed a deal with service provider Shin Nippon Biomedical Laboratories to collaborate in Japan, pooling resources in a joint venture designed to tap the growing market for clinical research there.
X-Chem, the biotech that operates from within PPD, signed a second agreement with partner Bayer, outlicensing a second discovery-stage program.
PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.
X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.
PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.
PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.